Efalizumab for Moderate to Severe Atopic Dermatitis
NCT00226057
·
clinicaltrials.gov ↗
PHASE1
Phase
COMPLETED
Status
10
Enrollment
OTHER
Sponsor class
Conditions
Dermatitis, Atopic
Interventions
DRUG:
Raptiva
Sponsor
Oregon Health and Science University